Author

Jacqueline McBride 1

1 Genentech, Inc.,South San Francisco,United States of America

ETROLIZUMAB COMPARED WITH ADALIMUMAB OR PLACEBO AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED, PHASE 3 HIBISCUS I & II TRIALS

Iris Dotan, Julian Panés, Aaron Duvall, Yoram Bouhnik, Graham Radford-Smith, Peter D.R. Higgins, Daniel S. Mishkin, Pablo Arrisi, Astrid Scalori, Young Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Stuart Lacey, Jacqueline McBride, David T. Rubin

ETROLIZUMAB TREATMENT IMPROVES HISTOLOGICAL ACTIVITY AS ASSESSED BY BOTH THE ROBARTS HISTOPATHOLOGY AND NANCY HISTOLOGICAL INDICES

Laurent Peyrin-Biroulet, Brian G. Feagan, Gert De Hertogh, David T. Rubin, Romeo Maciuca, Jacqueline McBride, Udaysankar Arulmani, Alexis Scherl

ETROLIZUMAB TREATMENT MODULATES MADCAM-1 LEVELS IN SERUM IN PATIENTS WITH CROHN'S DISEASE

William Sandborn, Julian Panés, Franklin Fuh, Rich Erickson, Rhian Jacob, Wenhui Zhang, Meina Tang, Jacqueline McBride

ETROLIZUMAB TREATMENT MODULATES MADCAM-1 LEVELS IN SERUM IN PATIENTS WITH CROHN’S DISEASE

Jacqueline McBride

Greater Reductions of Gut T Lymphocytes with Combined Blockade of α4β7 and αEβ7 Integrins Versus Individual Blockade Alone

Bingbing Dai, Ryan Ichikawa, Justin Elstrott, Alvin Gogineni, Mary E. Keir, Jacqueline McBride, Tangsheng Yi

Item 1 - 5 / 5
1